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Abstract: Anti-tumor necrosis factor (TNF) monoclonal antibodies and TNF receptor 
ectodomain fusion protein are in clinical use to neutralize circulating TNF and ameliorate 
symptoms of many autoimmune diseases and pathological conditions with chronic 
inflammation. In this paper we present data to prove that reverse signaling, elicited by 
agonist molecules interacting with the membrane-bound TNF of myeloid cells, 
significantly contributes to the therapeutic effect of these anti-TNF medicines. Interaction 
of agonist monoclonals with cell surface TNF significantly attenuates the expression of 
pro-inflammatory cytokines and induces changes in the production of extracellular and 
intracellular signaling molecules. This phenomenon is not dependent on the Fc portion of 
antibodies as Fab constructs are as efficient as full antibody molecules. 
Keywords: autoimmune; monoclonal antibodies; inflammation; macrophage; reverse 
signal; tumor necrosis factor (TNF); TNF receptor 
 
1. Introduction 
Tumor necrosis factor (TNF), a master regulator of inflammation, is a cytokine that has crucial roles 
in regulating the intensity of immune response, mobilizing immune cells against invading pathogens, 
dangerous “self,” and—in pathological conditions—healthy tissues [1]. TNF is a key mediator of 
lethal endotoxin poisoning and septic shock. Excessive production of this cytokine leads to serious, 
OPEN ACCESS
Antibodies 2015, 4 124 
 
frequently life-threatening pathological consequences, as revealed by Medzhitov [2]. TNF, as a 
powerful pro-inflammatory cytokine, is responsible for many of the clinical symptoms associated with 
autoimmune disorders. The presence of relatively low levels of TNF for extended periods of time can 
also lead to serious consequences, for example cachexia in malignant diseases. Some neurological 
disorders, like major depression or bipolar disorder [3], pulmonary diseases [4], cardiovascular 
diseases [5], and insulin resistance [6] are characterized as a consequence of enhanced TNF 
production. A drastically elevated TNF level is also demonstrated in chronic autoimmune diseases such as 
psoriasis [7], rheumatoid arthritis [8], Crohn’s disease [9], etc. 
In chronic inflammatory disorders and autoimmune diseases, the blockade of TNF by  
anti-TNF antibodies (infliximab [Remicade], adalimumab [Humira], golimumab [Simponi], and 
certolizumab pegol [Cimzia]) or receptor (p75) ectodomain-immunoglobulin Fc fragment fusion 
protein (Etanercept [Enbrel]) became the therapy of choice, though their exact mechanism of action is 
still not totally clear. The most frequently used anti-TNF antibody is infliximab (IFX). IFX is a 
chimeric antibody carrying the constant region of the human immunglobulin G1 (IgG1) [10]. 
Infliximab was first approved by the FDA for the treatment of Crohn’s disease in 1998 [11], and now 
it is also used for the treatment of rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing 
spondylitis, and ulcerative colitis. Unfortunately, long-term application of IFX provokes the development 
of anti-drug antibodies in a significant proportion (40%–45%) of the patients [12]. In these cases, 
change to another type of TNF-inhibitor, e.g., etanercept and certolizumab pegol (CZP), is the solution. 
CZP contains only the Fab fragment of the human monoclonal anti-TNF antibody, derivatized with 
polyethylene glycol (PEG). The presence of PEG extends the molecule’s serum half-life, allowing less 
frequent application [13]. Furthermore, as the constant fragment of IgG is absent from CZP, it can be 
applied in pregnancy. IgG is able to cross the placenta by active transport at the third trimester [14]. In 
contrast to antibodies, CZP penetrates the placenta only by passive diffusion, resulting in significantly 
lower CZP concentration in the cord blood as compared with monoclonals [15]. 
Though most activated immune cells (and several other cell types) are able to produce TNF, the 
most important source of circulating sTNF is macrophages, and most of the transmembrane TNF 
(mTNF) is present on activated macrophages. We have shown earlier that mTNF shows receptor-like 
properties [16] and several groups also reported that engagement of the transmembrane form of TNF 
with cognate receptor molecules or agonistic antibodies triggers a signaling event in TNF producing 
cells [17–19], defined as “reverse” signaling to distinguish it from “forward” signaling induced by 
activation of TNF receptors. 
In this paper we report the results of our investigations, specifically how agonistic antibody-elicited 
reverse signaling influences the expression of genes of several cytokines and intracellular signaling 
molecules in different myeloid cell lines. 
2. Materials and Methods 
2.1. Cell Culture 
THP-1, MonoMac6, and U937 human monocytic cell lines were obtained from American Type 
Culture Collection (ATCC; USA) and propagated in RPMI-1640 medium (Lonza), which was 
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supplemented with 10% heat-inactivated fetal bovine serum (FBS; Euro-Clone), 2 mM L-glutamine 
(Lonza), and 10 µg/mL kanamycin (Sigma). 
RAW264.7, DHO3, and J774 murine macrophages were grown in Dulbecco’s Modified Eagle 
Medium (DMEM; Lonza) in the presence of 10% heat-inactivated FBS (Euro-Clone), 2 mM  
L-glutamine (Lonza), and 10 µg/mL kanamycin (Sigma). Twenty-four hours before the experiments,  
5 × 105 cells were plated onto each well of a six-well plate (Sarstedt) in order to minimize the 
unwanted stress response during the experiments. Human and mouse cells were kept under standard 
cell culture conditions (37 °C in an atmosphere of 5% (v/v) CO2 in air). 
2.2. Cell Culture Stimulation 
To induce reverse signaling, monoclonal anti-TNF antibodies, namely infliximab (IFX; Schering-
Plough) and Certolizumab pegol (CZP; UCB Pharma), were used in a concentration of 10 µg/mL. For 
mimicking inflammatory milieux, Escherichia coli 055:B5 strain derived lipopolysaccharide (LPS; 
Sigma) was added in a concentration of 100 ng/mL. In some experiments, immunglobulin G (IgG; 
Human Bioplazma Ltd) stimulation (10 µg/mL) was used as a control. 
2.3. Bone Marrow-Derived Mouse Macrophages 
Six-week-old SPF C57/B6 female mice were purchased from Charles River. Animals were 
euthanized by cervical dislocation. Femurs and tibiae were removed and kept in RPMI-1640 cell 
culture media (Lonza), which was supplemented with 10% heat-inactivated FBS (Euro-Clones), 2 mM 
L-glutamine (Lonza), and 100 µg/mL kanamycin (Sigma) for further use. Bone marrow was removed 
from the bones by aspirating them with RPMI-1640 medium. Bone marrow was centrifuged at  
2000 rpm for 5 min. In order to remove erythrocytes, the cell pellet was resuspended in 2 mL 
ammonium chloride potassium lysis buffer (ACK, Lonza). An additional 8 mL of RPMI-1640 medium 
was added and cells were centrifuged. Bone marrow-derived cells were washed an additional two 
times with RPMI-1640 medium. Then, cells were resuspended in a DMEM high glucose medium 
(Lonza), which was supplemented with 15% heat-inactivated FBS, 20% conditioned L929 cell culture 
supernatant (which was used as a source of M-CSF), and 100 µg/mL kanamycin (Sigma). Five × 105 
cells were plated onto six-well tissue culture plates (Sarstedt). Two days later, cells were washed with 
phosphate buffered saline (PBS; Lonza) and a complete DMEM cell culture medium was added. Three 
days later (hereafter defined as Day 1), cells were washed again and fresh DMEM was added. Of the 
resulting population, 93.5%–96.2% consisted of CD11b+, F4/80+ macrophages with the majority being 
Ly-6C−, Ly-6G−, and c-Fms+. 
2.4. Quantitative Reverse Transcriptase Polymerase Chain Reaction (QRT-PCR) 
Total RNA was extracted from cell cultures at different time points after stimulation using GeneJet 
RNA Purification Kit (Thermo Scientific) according to the manufacturer’s instructions. The quality and 
quantity of the extracted RNA were determined by photometric measurements (BioPhotometer, Eppendorf). 
cDNA was synthesized from more than 500 ng of total RNA by using the Maxima First Strand 
cDNA Synthesis Kit for RT-qPCR (Thermo Scientific) based on the instructions of the manufacturer. 
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The relative abundance of selected mRNA was determined by QRT-PCR by using Bio-Rad CFX96 
System (Bio-Rad). Reactions were performed using the Luminaris Color HiGreen No ROX qPCR 
Master Mix (Thermo Scientific). The primer sets used in QRT-PCR are listed in Table 1. As controls, 
reaction mixtures without cDNA were used. All of the experiments were performed in duplicate with 
at least three biological replicates. The ratio of each mRNA is relative to glycerinaldehide-3-
phosphate-dehydrogenase (GAPDH) and calculated using the ∆∆Ct method. 
Table 1. Specific exon–exon spanning primer sets used in QRT-PCR experiments.  
(A) human; (B) mouse. (Expression of a number of other genes was also investigated; here 
primers of only those genes that are discussed in this paper are presented). 
A 
Target name Forward (5'→3') Reverse (3'→5') 
GAPDH CAGTCAGCCGCATCTTCTTTTG CGCCCAATACGACCAAATCC 
TNF GCCTCTTCTCCTTCCTGATCG GCTTGAGGGTTTGCTACAACAT 
CKIP-1 ACCTGCAACCGACGATTCTT CATTCCATGAAGTCAGCGATATGT 
IL-1β CCACCTCCAGGGACAGGATA TTTGGGATCTACACTCTCCAGC 
IL-6 GGATTCAATGAGGAGACTTGCC CTGGCATTTGTGGTTGGGTC 
IL-8 ACTCCAAACCTTTCCACCCC TTCTCAGCCCTCTTCAAAAACTTC 
IL-10 GGCACCCAGTCTGAGAACAG GGCAACCCAGGTAACCCTTAAA 
CXCL9 AGTGCAAGGAACCCCAGTAG TCACATCTGCTGAATCTGGGTT 
ICAM1 TGTGACCAGCCCAAGTTGTT TGGAGTCCAGTACACGGTGA 
TGF-β ACCAACTATTGCTTCAGCTCCA CTTGCTGTACTGCGTGTCCA 
TNFAIP3 GCTGAAAACGAACGGTGACGG AGAGACTCCAGTTGCCAGCGG 
B 
GAPDH CTGGAAAGCTGTGGCGTGAT ATACTTGGCAGGTTTCTCCAGG 
TNF TAGCCCACGTCGTAGCAAAC GCAGCCTTGTCCCTTGAAGA 
CKIP-1 GGATGAGGTCACCGTTGAGG CGGAAGCTCTCAGCACAAGA 
CXCL10 TCATCCTGCTGGGTCTGAGT TCATCGTGGCAATGATCTCAACA 
IL-1β AACCTTTGACCTGGGCTGTC CAGAGGATGGGCTCTTCTTCAA 
2.5. Data Representation and Statistical Analysis 
Bars show the average ± standard error of the mean (SEM). The significance of differences between 
sets of data was determined by Student’s paired t-test or One-Way ANOVA following the Neuman–
Keuls post hoc test using GraphPad Prism for Windows. A probability value (p) of less than 0.05 was 
considered significant. 
3. Results 
3.1. Infliximab Stimulation Attenuates the LPS-Induced Gene Expression of Pro-Inflammatory 
Molecules in THP-1 Cells 
In previous reports, we and others [16] have shown that reverse signaling influenced the 
transcription activity of different genes, and Mitoma and colleagues reported induction of apoptosis 
and cell cycle arrest in transmembrane TNF-expressing Jurkat T cells [20]. To investigate this 
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phenomenon at relative gene expression level, THP-1 human monocytes were treated with IFX and/or 
LPS according to the model described at Figure 1A. In brief, cells were exposed to 10 µg/mL IFX and 
30 min later IFX was removed and the cells were challenged with LPS in a concentration of  
100 ng/mL or left untreated. After four hours the cells were washed with PBS and resuspended in fresh 
cell culture medium. Another four hours later, total RNA was extracted and QRT-PCR experiments 
were performed as described in the Materials and Methods section. 
As was reviewed by Akira and his colleagues, the activation of the TLR4 by bacterial LPS results in 
the phosphorylation of the members of the MAP kinase cascade, which leads to the activation of the 
nuclear factor kappa B (NF-κB) [21]; thus, it was not surprising that LPS stimulation alone resulted in 
remarkable upregulation of relative gene expression in the case of pro-inflammatory cytokines and 
chemokines (Figure 1B). While IFX treatment alone had practically no impact on the relative gene 
expression pattern of the investigated molecules, IFX pretreatment of the cells significantly attenuated 
the effect of LPS challenge. This finding suggests that reverse signaling elicited by IFX treatment has 
a regulatory role only under inflammatory conditions. Neutralization of soluble and mTNF by  
anti-TNF antibodies inhibits TNF receptor signaling, which influence the expression of genes of 
inflammatory cytokines in activated myeloid cells. Previous experiments with NF-κB-luc transformed 
THP-1 cells (Fejer G. and Kusz E. unpublished data) [22] showed that LPS challenge induced a 
dramatic increase in NF-κB activity that returned to pre-treatment levels within 3 h. In the present 
experiments we followed the changes in gene activity at least 4 h after LPS treatment, when TNF 
receptor signaling already faded away. 
Although IL-10 is mostly characterized as an anti-inflammatory cytokine that interferes with  
pro-inflammatory cytokine production and inhibits the antigen-presenting capacity of macrophages 
and dendritic cells [23], our data demonstrate remarkable similarity between the expression patterns of 
IL-10 and pro-inflammatory cytokines. A more complex role of IL-10 is also emerging from recent 
publications [24]. Synovial fluid-derived macrophages isolated from rheumatoid arthritis (RA) patients 
produced higher levels of IL-10 than peripheral blood mononuclear cells of the same patients or 
healthy individuals [25,26]. 
Casein kinase 2-interacting protein 1 (CKIP-1) was previously identified by yeast-two hybrid 
experiments as a protein interacting with the cytoplasmic domain of TNF. We have shown that during 
reverse signaling it translocates with the processed N-terminal fragment of TNF from the plasma 
membrane onto the cytoplasm [18]. In the present experiments the gene of CKIP-1 was the only one 
that was induced both by IFX stimulation and LPS challenge. 
3.2. The Effect of Infliximab Does Not Depend on Its Fc Fragment 
The primary therapeutic role of IFX is neutralization of the circulating TNF. There are publications 
describing its cytotoxic- [20] and reverse signal-inducing effects on mTNF-producing cells [27]. The 
chimeric IFX contains the constant fragment of human IgG1 (Fc) that is required for complement 
fixation and antibody-dependent cell-mediated cytotoxicity (ADCC). On the other hand, reverse 
signaling is elicited only by the interaction of mTNF with the agonist Fab—at least theoretically. 
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Figure 1. The induction of reverse signaling with IFX on THP-1 cells alters the expression 
pattern of inflammation-related effector molecules. (A) THP-1 human monocytes were 
treated with IFX and/or LPS. Total RNA and cell culture supernatants were collected 8 h 
post-IFX treatment. (B) IFX treatment alone had no significant impact on relative gene 
expression pattern of the genes, with the notable exception of CKIP-1. The CKIP-1 protein 
is involved in inflammation and in reverse signaling. Bars show means ± SEM from at 
least three independent experiments. * Significantly different from controls (One-Way 
ANOVA, following the Neuman–Keuls post hoc test). 
Antibodies 2015, 4 129 
 
In order to test the role of the constant fragment of IFX on human (Figure 2A) and mouse monocyte 
and macrophage cell lines (Figure 2B), they were exposed to IFX or IgG1 for a day or left untreated. 
RNA isolation was performed 24 h later. In all human cell lines, IFX stimulation decreased the relative 
expression of TNF and IL-1β genes as compared with naïve and IgG treated samples. In the case of 
other genes, different cells responded in different ways to both IFX and IgG1, probably reflecting 
differences in the density and ratio of Fc receptors and TNF molecules on the cell surface. 
 
Figure 2. The effect of IFX is not dependent on the presence of the constant region (Fc) of 
IgG. Although IFX is a chimeric antibody that contains the Fc fragment of human IgG1, 
and myeloid cells carry Fc receptors, distinct relative gene expression patterns were 
demonstrated after IFX or IgG challenge in all investigated cell lines. To verify that the 
effect of reverse signaling is different from that of FcR signaling, the relative gene 
expression pattern of inflammation-related effector molecules were investigated in human 
(A) and mouse (B) monocytic cell lines 24 h after IFX or IgG stimulation. All of the 
investigated molecules show distinct relative gene expression pattern after IFX stimulation 
as compared with IgG treatment. Data show average ± SEM from at least three 
independent experiments. * Significantly different from controls (One-Way ANOVA 
following Neuman–Keuls post hoc test). 
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In mouse macrophage cells moderate downregulation of relative gene expression of IL-1β was 
measured 24 h after IFX treatment. In the cases of TNF, CKIP-1, and CXCL10, as in human cell lines, 
no gene- or treatment-specific tendencies were observed. However, in practically all cases the effect of 
IFX on a certain cell line was dissimilar from the effect of IgG1 on the same cells. We might conclude 
that the effect of infliximab could be influenced by, but does not depend on, its Fc fragment. 
3.3. The Induction of Reverse Signaling by Monoclonal Antibodies Modulates the Expression Pattern 
of Cytokines and Chemokines in a Time-Dependent Manner  
As monoclonal anti-TNF antibodies are widely used in autoimmune inflammatory diseases, we next 
aimed to test their impact on THP-1 human monocytes under inflammatory conditions. THP-1 cells 
were challenged with bacterial LPS for 2 h before anti-TNF treatment. In this study, we also tested the 
effect of certolizumab pegol (CZP) on the gene expression of cytokines and chemokines. 
Measurement of relative gene expression was carried out 4 and 8 h after anti-TNF treatment. In 
order to test the dependence of IFX on the presence of the Fc fragment, in parallel with anti-TNF 
stimulation, IgG challenge was performed. 
IgG treatment increased the expression of IL-8 but had no significant alteration on the gene 
expression patterns of investigated effector molecules as compared with controls 4 h post-treatment. 
The relative gene expression of all investigated genes was downregulated by 8 h after IgG treatment as 
compared with 4 h samples; however, the statistical significance was demonstrated only in the case of 
TNF (Figure 3A) and IL-1β (Figure 3D). 
The application of different anti-TNF antibodies under inflammatory conditions resulted in 
significant decrease of relative gene expression as compared with either IgG stimulated samples or 
controls. The regulatory effect of the monoclonals is a time-dependent phenomenon, as 8 h after 
stimulation more robust relative gene expression decrease was detected compared with earlier time 
points. In accordance with our previous findings, the regulatory effect of IFX seems to be very 
different than that of IgG1, as IFX treatment resulted in significant decrease of the relative expression 
of TNF (A), IL-8 (C), and IL-1β (D) genes as compared with IgG-treated samples or controls at all 
investigated time points. 
IFX slightly decreased the expression of the CKIP-1 gene, as did IgG1 at 8 h and CZP at 4 h. 
However, in the investigated cell lines neither IgG nor the monoclonal treatment caused significant 
changes in the expression of this gene. 
3.4. Certolizumab Pegol Decreases the Relative Gene Expression of Inflammation-Related Effector 
Molecules in a Time-Dependent Manner under Inflammatory Conditions 
In order to investigate the transcriptional effect of CZP-elicited reverse signaling in an 
inflammatory setting, THP-1 (Figure 4A) and U937 (Figure 4B) human monocytes were pretreated 
with LPS for two hours, then cells were exposed to 10 µg/mL CZP to induce reverse signaling. Total 
RNA was harvested 4, 8, and 24 h after CZP treatment. 
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Figure 3. Induction of reverse signaling by distinct anti-TNF monoclonals modulates gene 
expression patterns in a time-dependent manner. Relative gene expression pattern of TNF 
(A), CKIP-1 (B), IL-8 (C), and IL-1β (D) were investigated by QRT-PCR on THP-1 
human monocytes. To induce inflammatory response, LPS treatment was performed. Two 
hours post-LPS challenge, samples were stimulated with IgG1, IFX, or CZP, respectively. 
RNA was isolated from the cells four and eight hours after stimulation. IFX- and  
CZP-treated samples showed comparable effect on the gene expression of inflammatory 
cytokines, although CZP does not carry any Fc fragment. Data show average ± SEM from 
at least three independent experiments. * Significantly different from unstimulated controls  
(One-Way ANOVA following Neuman–Keuls post hoc test). 
In THP-1 cells (Figure 4A), CZP treatment significantly decreased the relative gene expression of 
TNF, IL-8, IL-10, and IL-1β compared with untreated samples 4 h after anti-TNF treatment. An even 
more pronounced relative gene expression decline was detected at later time points, reaching the 
minimum level at 24 h after stimulation. In contrast to the above cytokines—and in accordance with 
our previous findings—the gene of CKIP-1 demonstrated an opposite pattern. Although at first a slight 
decrease was detected in relative gene expression (4 h after CZP treatment), at subsequent time points 
a minor upregulation of relative gene expression was demonstrated, as compared with the 4 h samples 
or untreated control, though the increase was not significant. 
THP-1 and U937 cells have developed into myeloid leukemia cell lines as a result of mutations 
causing different differentiation abnormalities. These cell lines represent different myeloid lineages 
and frequently respond to different stimuli in different ways. CZP-induced reverse signaling changed 
the gene expression pattern of IL-8 and L-10 in U937 cells (Figure 4B); like in THP-1 cells, the 
relative expression of these genes showed a decline in a time-dependent manner. 
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Figure 4. The effect of CZP-induced reverse signaling on LPS-induced gene expression in 
THP-1 and U937 human monocytes. THP-1 (A) and U937 (B) human monocytes were 
pretreated with LPS to induce inflammatory response. Two hours later, CZP was added. 
Total RNA was harvested 4, 8, and 24 h after the addition of CZP. The regulatory effect of 
CZP treatment was time-dependent. In the case of both THP-1 and U937 cells, mild 
relative expression upregulation was detected in the CKIP-1 gene, suggesting the induction 
of reverse signaling. Data show the average ± SEM from at least three independent 
experiments. * Significantly different from unstimulated controls (One-Way ANOVA 
following Neuman–Keuls post hoc test). 
On the other hand, the expression pattern of the two principal pro-inflammatory cytokines, TNF and 
IL-1β, showed fairly interesting time courses. The relative gene expression of TNF was moderately 
downregulated 4 h after CZP challenge, turning into significant upregulation after another 4 h. Finally, 
the long term effect of reverse signaling was a dramatic decrease in the relative expression of the TNF 
gene. In the case of IL-1β, a decrease of relative gene expression was detected 4 h post-CZP challenge, 
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which dropped further at 8 h after CZP treatment (with statistical significance as compared with 
untreated samples). Here again, the long-term effect was the opposite: 24 h after treatment, we 
repeatedly detected a moderate relative gene expression upregulation. 
The different myeloid cell lines used in the experiments represent macrophages with different 
differentiation patterns, expressing different markers. Summarizing the above experiment, we can say 
that in all these cell lines anti-TNF monoclonal-induced reverse signaling resulted in attenuation of 
expression of pro-inflammatory genes and IL-10. This can significantly contribute to the beneficial 
therapeutic effect of anti-TNF antibodies in autoimmune and chronic inflammatory diseases. 
3.5. The Regulatory Effect of IFX Treatment on Activated Bone Marrow-Derived Mouse Macrophages 
Primary bone marrow-derived macrophages were differentiated from C57/B6 SPF mice by standard 
protocol. Cells were treated with phorbol 12-myristate 13-acetate (PMA, Sigma, 100 nM final 
concentration). On Day 2, cells were washed twice with PBS and fresh cell culture medium was added. 
Reverse signaling was induced by IFX treatment. Relative gene expression studies were carried out  
24 h after IFX (or IgG) stimulation. 
IFX-induced reverse signaling remarkably reduced the relative gene expression of TNF and CXCL9 
(Figure 5A,D, respectively) as compared with PMA-stimulated control cells. On the other hand, in the 
case of CXCL10 or PDCD1, and ICAM-1 (Figure 5C,E,F, respectively), moderate or significant 
upregulation was detected. IFX and IgG stimulation clearly had different effects on gene expression of 
different cytokines, especially in the cases of PDCD1 (Figure 5C) and ICAM-1 (Figure 5F). 
 
Figure 5. IFX (and IgG) treatment of PMA-induced primary mouse macrophages. Primary 
mouse macrophages were activated by PMA and IFX or IgG stimulation was performed. 
PMA-stimulated cells were used as control. The relative gene expression pattern of TNF 
(A), IL-1β (B), PDCD1 (C), CXCL9 (D), CXCL10 (E), and ICAM1 (F) were determined 
by qRT-PCR 24 h after the induction of reverse signaling. Bars show means ± SEM from 
at least three independent experiments. * Significantly different (One-Way ANOVA, 
following Neuman–Keuls post hoc test). 
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Next, we examined how IFX induced reverse signaling acts on BMDMs under inflammatory 
conditions. For this, 24 h before IFX or IgG treatment, cells were stimulated with E.coli-derived LPS, 
an inflammatory ligand of TLR-4 [21,28]. Compared to control cells, IFX treatment downregulated 
relative the gene expression of all investigated effectors (Figure 6A,F). On the other hand, IgG 
treatment resulted in relative gene expression increase in case of PDCD1 (C) and expression of 
CXCL9 (D), CXCL10 (E), and ICAM-1 (F) was also lower as compared with control samples. These 
data suggest that IFX-induced reverse signaling has a modulatory role under inflammatory conditions 
(mostly on M1-like macrophages), which may explain the beneficial effect of anti-TNF antibodies in 
autoimmune inflammatory diseases. 
 
Figure 6. The effect of IFX on LPS-challenged primary mouse macrophages. Macrophages 
were activated by the presence of LPS before IFX treatment. Relative gene expression of 
TNF (A), IL-6 (B), PDCD1 (C), CXCL9 (D), CXCL10 (E), and ICAM-1 (F) was 
determined by qRT-PCR. LPS- and IgG-treated, as well as only LPS-stimulated, samples 
were used as controls. Bars show average ± SEM from at least three independent 
experiments. * Significantly different (One-Way ANOVA, Neuman–Keuls post hoc test). 
In other experiments (Figure 7), the response of bone marrow-derived primary mouse macrophages 
was investigated in the absence of inflammatory stimuli (under naïve conditions). When the cells were 
not exposed to LPS one day earlier, IFX-induced reverse signaling caused only minor regulatory 
effects on the relative gene expression pattern of TNF (Figure 7A), CXCL9 (D), CXCL10 (E), and 
ICAM-1 (F). It is important to note here that this expression pattern shows strong correlations with our 
results obtained from THP-1 human monocytes (Figure 1). In the case of IL-1β (Figure 7B), IFX 
treatment resulted in significant relative gene expression downregulation as compared with naïve cells, 
while it strongly increased the expression of PDCD1 (C). IgG exposure increased the expression of 
TNF (A), ICAM-1 (F), and especially CXCL-10 (D). IFX and IgG treatments had opposing effects on 
the expression of TNF (A), PDCD1 (C), and ICAM-1 (F). 
We can conclude that in the case of most effector molecules, the gene regulatory function of reverse 
signaling is restricted to inflammatory conditions. Its PDCD1-inducing effect on naïve BMDMs is 
interesting and might play a role in polarization of macrophages. 
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Figure 7. IFX-elicited reverse signaling had a marginal effect in the absence of inflammatory 
conditions. Naïve bone marrow-derived mouse macrophages were treated with IFX, IgG, 
or left unstimulated. Relative gene expression of TNF (A), IL-1β (B), PDCD1 (C), CXCL9 
(D), CXCL10 (E), and ICAM-1 (F) was determined 48 h after IFX or IgG stimulation. 
Bars show the average ± SEM from at least three independent experiments. * Significantly 
different (One-Way ANOVA, following Neuman–Keuls post hoc test). 
4. Discussion 
LPS tolerance evolved to prevent the tissue-damaging effects of excessive inflammation. 
Reverse signaling of the TNF superfamily (recently reviewed by Juhász et al. [29] is also a 
regulatory mechanism, exerting—in different settings—both activating and inhibitory effects. The  
26 kDa membrane-bound TNF (mTNF) is processed by TACE (TNF converting enzyme, ADAM17), 
liberating the soluble cytokine. sTNF can interact with the 55kDa TNF receptor TNFRI and the  
75 kDa TNFR-II [30]. While TNFR-I is present on the surface of all nucleated cells, expression of 
TNFR-II is restricted to neurons, endothelial cells, and professional immune cells. TNFR-I possesses a 
death domain (DD) that can initiate apoptosis but can also activate the NF-kB and the p38 pathways to 
grant survival or induce proliferation, respectively. TNF-elicited responses (changes induced by 
receptor activation by cognate ligand) are regarded as “forward” signaling. 
However, when mTNF-producing cells bind to cell surface receptors, soluble receptors, or agonistic 
antibodies, the interaction also induces signaling in ligand-expressing cells (hereafter defined as 
reverse signaling, outside-to-inside signaling, or bidirectional signaling) [17] (Anti-TNF antibodies are 
regarded as antagonistic as far as inflammation and TNF receptor signaling is concerned. However, 
when induction of reverse signaling is concerned, the active ones are regarded as agonistic.) The 
cytoplasmic N terminus of mTNF contains a nuclear localization signal and during reverse signaling 
translocates into the nucleus and modifies—among others—the expression pattern of inflammation-
related genes [16]. Although this fine tuning of the immune response is believed to be one of the most 
important roles of TNF reverse signaling, it is also necessary for the appropriate axonal development 
during embryogenesis [31] and it has a pivotal role in nociceptor development [32]. Until now,  
19 ligands and 29 receptors of the TNF family members have been identified [33], and reverse 
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signaling was demonstrated in all cases investigated (Fas Ligand [34], BAFF [35], CD137 Ligand [36], 
and GITRL [37]). 
Neutralization of sTNF by the monoclonals was demonstrated in the case of IFX, CZP, etanercept, 
and adalimumab [38]. The impressive effects of anti-TNF agents suggest that other mechanisms may 
also contribute to efficacy. Antibody-dependent cell-mediated cytotoxicity (ADCC) and complement 
activation (CDC) may also play a role in this phenomenon [20]. 
TNF reverse signaling might also contribute to the therapeutic effect as it is shown in this paper to 
be able to downregulate expression of pro-inflammatory genes. The effects we observed are not 
consequences of inhibition of autocrine TNF receptor signaling on macrophages by TNF neutralizing 
agents. LPS-induced TNF production is restricted for short periods of 1–2 h, unless the cells are also 
exposed to adenoviruses [39]. In our in vitro experiments, we did not observe reverse signal-induced 
apoptosis of myeloid cells, only changes in the expression of genes and the production of cytokines. 
Our data strongly suggest that IFX stimulation before or after LPS challenge drastically downregulates 
the relative gene expression of inflammation-related effector molecules in THP-1 human monocytes. 
These data show strong correlations with the results of Domonkos (IL-1beta) [16], Eissner (IL-1, IL-6, 
and IL-10) [40], and Mitoma (IL-1beta) [20]. It is also known that IFX treatment robustly downregulates 
the relative expression of the IL-6 and CCL1 genes in Staphylococcus aureus-derived peptidoglycan 
stimulated primary human dendritic cells [41]. The interesting, opposing effects of both IFX and IgG 
on PDCD1 expression of PMA- and LPS-stimulated cells should be further investigated, as this receptor 
seems to play an important role in the polarization of macrophages [42] and immune suppression. 
Our research group has previously demonstrated that CKIP-1 interacts with AP-1/c-Jun [40], and 
CKIP-1 can also interact with a wide variety of proteins, including Akt, ATM, IFP35/Nmi, and 
Smurf1; thus, it can induce a wide variety of physiological processes, such as changes in cell motility, 
proliferation, differentiation, or cell death [18]. Both forced CKIP-1 overexpression and TNF reverse 
signaling increase the apoptotic tendency of myeloid cells when induced separately, but interfere with 
each other to promote survival if applied simultaneously. This and the fairly unpredictable expression 
of CKIP-1 in macrophages need to be further investigated [18]. 
The bone marrow-derived mouse macrophages and human and mouse myeloid cell lines studied in 
this report represented cells with different routes of differentiation and (in the case of leukemic cells) 
different defects of development. According to their origin and activation state, reverse signaling 
evoked different, sometimes opposing effects on the expression of certain genes in these cells. 
However, as far as the therapeutic importance of anti-TNF biologicals is concerned, the  
anti-inflammatory effect of reverse signaling seems to be the most important in activated inflammatory 
macrophages. The primary function, neutralization of soluble TNF, is only one factor to achieve the 
therapeutic effects of anti-TNF monoclonals. Further mechanisms, including CDC, ADCC, and TNF 
reverse signaling-induced attenuated expression of inflammatory cytokines and increased apoptosis of 
specially activated macrophages (e.g., pathological synovial macrophages but not normal 
macrophages), are also contributing to the efficacy of these agents [24]. 
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5. Conclusions 
Activated macrophages and TNF play decisive roles in the development of pathological symptoms 
of autoimmune and chronic inflammatory diseases. Anti-TNF biologicals are used in the clinic to 
attenuate these symptoms by neutralizing soluble (and cell-associated) TNF. It is an unexpected 
development that anti-TNF monoclonals do more than that. By binding to the transmembrane form of 
TNF on activated macrophages, they activate reverse signaling, an intracellular signaling pathway that 
leads to the modification of gene activity pattern. As shown in the reported experiments, reverse 
signaling interferes with the production of inflammatory mediator molecules, contributing to the  
long-term therapeutic effects of anti-TNF antibodies. 
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